BridgeBio Pharma (BBIO) Reportable Segment — Restructuring, impairment, and related charges

Screener

Similar metrics at other companies

QUADInternational — Restructuring, impairment and transaction-related charges, net

$3.3M+1,550%

MZTINonallocated Restructuring and Impairment Charges — Restructuring, Impairment and Other, Net

$261K-79.5%

QUADUnited States Print and Related Services — Restructuring, impairment and transaction-related charges, net

$5.8M-32.6%

ADIReportable Segment — Special charges, net

$0-100%

SBUXInternational — Restructuring and impairments

$41.1M+1,226%

DOWIndustrial Intermediates & Infrastructure — Restructuring and asset related charges - net

$1M-98.9%

Other financials

Income statement

See full

Revenue$194.5M+66.8%

Gross profit$184.6M+61.9%

Operating income-$106.0M-1.5%

Net income-$166.6M+1.8%

EPS (diluted)-$0.84+4.5%

Balance sheet

See full

Cash & equivalents$882.0M+62.5%

Total debt$3.3B+32,101%

Total equity-$2.3B-38.2%

Total assets$1.4B+55.5%

Cash flow

See full

Operating cash flow-$197.3M+1.0%

CapEx$69.0K—

Free cash flow-$197.3M+0.9%

Valuation

See full

Market cap$16.06B+87.5%

Enterprise value$18.44B+136%

P/S27.7×-8.6×

Profitability

See full

Gross margin95.1%-0.2pp

Operating margin-90.5%-41.2pp

Net margin-125.9%-54.5pp

FCF margin-76.8%—

Returns & leverage

See full

Return on equity-216.8%—

Debt / equity2×—

Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:RestructuringSettlementAndImpairmentProvisions.

The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.

Filed: May 7, 2026, 4:31 PM EDT
Fiscal quarter: Q1 FY2026
Calendar quarter: Q1 2026
Accession: 0001743881-26-000019

Line item	Three Months Ended March 31, 2026	2025
Other research programs	16,916	18,007
Total segment research and development	126,636	111,431
Selling, general and administrative	163,896	106,365
Restructuring, impairment, and related charges	—	570
Total operating costs and expenses	300,471	221,005
Loss from operations	(105,956)	(104,372)
Other income (expense), net:
Interest income	6,246	5,385

Item 1. Financial Statements (Unaudited)

FAQ

What is BridgeBio Pharma's reportable segment — restructuring, impairment, and related charges?: BridgeBio Pharma (BBIO) reported reportable segment — restructuring, impairment, and related charges of $0 in Q1 2026.
How has BridgeBio Pharma's reportable segment — restructuring, impairment, and related charges changed year-over-year?: BridgeBio Pharma's reportable segment — restructuring, impairment, and related charges decreased by 100.0% year-over-year, from $570K to $0.
What does reportable segment — restructuring, impairment, and related charges mean?: Reflects non-recurring costs associated with organizational restructuring, asset write-downs, or impairment of intangible assets within the segment. These charges often signal strategic shifts or asset underperformance.